MiniMed Posts Double-Digit Sales Growth, Widening Net Loss

Why It Matters

The results highlight strong market demand for diabetes‑tech solutions while exposing the profitability challenges MiniMed must overcome as an independent public company.

Key Takeaways

• Revenue rose 15% to $790 million in FY26 Q3.
• Net loss expanded to $119 million, up from $10 million year‑over‑year.
• FDA‑cleared MiniMed Flex pump fuels product pipeline.
• Abbott partnership expected to boost CGM sales.
• $309 million IPO proceeds retained for growth initiatives.

Pulse Analysis

MiniMed, the diabetes‑technology spin‑off of Medtronic, entered the public markets in March 2026, raising roughly $309 million in IPO proceeds. The company’s third‑quarter results underscore a swift transition from a Medtronic subsidiary to an independent player, with revenue climbing 15 % to $790 million. This growth reflects heightened demand for automated insulin‑delivery solutions as the global diabetes market, projected to exceed $100 billion by 2030, accelerates adoption of connected devices. Investors are watching MiniMed’s ability to translate top‑line momentum into sustainable earnings.

The revenue surge is anchored by MiniMed’s latest product lineup. FDA clearance for the MiniMed Flex, a compact insulin pump, expands the firm’s hardware portfolio, while the Simplera Sync continuous glucose monitor, already approved, positions MiniMed alongside leading CGM providers. A strategic partnership with Abbott, a heavyweight in glucose‑monitoring, is expected to broaden distribution channels and drive recurring sensor sales. Together, these innovations aim to lock patients into an integrated ecosystem, a model that has proven lucrative for rivals such as Dexcom and Insulet.

Despite the sales lift, MiniMed posted a $119 million net loss, a sharp widening from the $10 million loss reported a year earlier. The loss reflects heavy R&D spend, marketing outlays for the new pump family, and the costs of establishing a standalone corporate infrastructure. Medtronic’s plan to unwind its roughly 90 % stake by year‑end adds another layer of financial complexity, as the parent seeks to monetize its investment while ensuring a smooth transition. Analysts will gauge whether the company can narrow the loss gap as product adoption scales and whether the Abbott tie‑up can deliver the anticipated revenue runway.